Nurix Therapeutics

Company snapshot

Important Notice to Candidates: Nurix representatives with never conduct interviews by text and will never request personal financial information or ask candidates to purchase equipment. At Nurix Therapeutics, we aim to fundamentally change the way disease is treated using degrader-based medicines. Our journey began with a vision to harness the power of the cell’s natural protein degradation machi

• 9 active pipeline program(s) linked via ClinicalTrials.gov.
• 14 US patent(s) indexed to this assignee profile.
• 9 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Nurix Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Nurix Therapeutics.

1. Jun 8, 2026 Clinical update

   IP — Phase 1

2. Jun 5, 2026 Clinical update

   NX-5948 — Phase 2

3. Jun 5, 2026 Clinical update

   NX-1607 — Phase 1

4. May 26, 2026 Clinical update

   A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies — Phase 1

5. May 23, 2026 Clinical update

   NX-5948 — Phase 3

View all clinical trial activity →

• What is Nurix Therapeutics?

  Nurix Therapeutics is a pharma organization headquartered in Brisbane, USA. It trades on NYSE under ticker NRIX. Primary therapeutic focus areas include Chronic Lymphocytic Leukemia (CLL), Relapsed/Refractory B-cell Malignancies, Platinum-resistant Ovarian Cancer, Ovarian Cancer,

• Is Nurix Therapeutics publicly traded?

  Yes. Nurix Therapeutics is listed with ticker NRIX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Nurix Therapeutics develop or market?

  We link 4 drug profile(s) where Nurix Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/nurix-therapeutics#company-drugs.

• What are the latest developments for Nurix Therapeutics?

  In the last 12 months our linked public records show 9 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Nurix Therapeutics focus on?

  Nurix Therapeutics focuses on Chronic Lymphocytic Leukemia (CLL), Relapsed/Refractory B-cell Malignancies, Platinum-resistant Ovarian Cancer based on our analysis of their pipeline programs and drug development activities.